Dupilumab

/Dupilumab

Dupilumab Study – Subject Patient Comments

By | April 6th, 2017|Dupilumab|

The Dupilumab studies were 16 weeks long. This is a very short time to truly evaluate a drug in this very difficult and prolonged skin problem. In addition, there were no objective comments on rash, redness, skin oozing, edema and pain. There are no long term follow ups reported. But: Links to patient comments after [...]

Dupilumab Study – Are Eczema Patients Being ‘duped’ Again?

By | April 4th, 2017|Dupilumab|

My most recent postings have dissected the protocol, the patients, the methods and the fine print of the Dupilumab studies reported in the medical literature. Severe failings are evident in all the above criteria. What, therefore can we expect from the results and conclusions? This assessment will group together all Dupilumab studies. My findings are: [...]

Dupilumab – Does the Drug Work?

By | April 3rd, 2017|Dupilumab|

The Dupilumab studies as reported in the New England Journal of Medicine and the Journal of the American Academy of Dermatology and by me on discussed in my four prior posts exhibit multiple violations in the study of new drugs and scientific reporting. Inclusion of patients: from my experience with 4000 totally similar patients none [...]

Dupilumab – Horror Movie

By | March 31st, 2017|Dupilumab|

In recounting the diagnosis, management and cure of 4000 corticosteroid addicted atopic dermatitis patients I feel like I am in a futuristic movie with a split screen simultaneously showing two similar populations. One population is now in the present consisting of suffering patients who go on to CURE – albeit through a prolonged period of [...]

Dupilumab Study – Journal Articles

By | March 30th, 2017|Dupilumab|

Dupilumab is now FDA approved as of March 28, 2017 and this event necessitates a further evaluation for the prospects of this drug helping eczema patients. Physicians and patients are being told the published results but they deserve an objective critique. There are multiple discrepancies and violations of true, honest research and in looking at [...]

Dupilumab: Further Comments

By | March 28th, 2017|Dupilumab|

After having cured 4000 plus patients with steroid addiction and Red Skin Syndrome, I feel duty bound to offer sound advice to those still mismanaged suffering patients still floundering in their care. In that regard I look at every new drug offering promise of improvement or cure to these patients. I dissect the quality of [...]

Dupilumab Study

By | March 22nd, 2017|Dupilumab, RSS Patients|

The following are comments by Marvin Rapaport MD, owner of this website, Red Skin Syndrome, and edited and clearly written by an esteemed writer and journalist, Ruchy Reese, who writes for the monthly magazine, Wellspring.   I am writing in response to an article that appeared in the December 15, 2016 edition of the New [...]

Letter to Editor of JAAD

By | November 30th, 2016|Dupilumab, Topical Steroid Withdrawal|

  November 17, 2016   Bruce H. Thiers, MD c/o Detra Davis, Managing Editor Journal of the American Academy of Dermatology 930 E Woodfield Rd Schaumburg, IL 60173   Dear Dr. Thiers: Please review the two enclosed “letters to the Editor” with an open mind. I am appealing to your scientific nature as a doctor [...]

Ethics in Drug Studies

By | November 30th, 2016|Dupilumab, RSS Patients|

November 17, 2016 Bruce H. Thiers, MD c/o Detra Davis, Managing Editor Journal of the American Academy of Dermatology 930 E. Woodfield Rd Schaumburg, IL 60173   Re: Ethics in Drug Studies To the Editor:   Dupilumab (JAAD 2016, 75; 506-516) by Simpson et al has three glaring ethical concerns: Protocol: There is no mention [...]